{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-097881","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.770580+00:00","generated_at":"2026-05-18T03:31:39.616366+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026","bullets":["Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.","Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).","ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.","Restructuring and program cuts expected to extend cash runway into Q4 2026.","ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-097881","json":"https://secwatch.observer/filing/0000950170-25-097881.json","markdown":"https://secwatch.observer/filing/0000950170-25-097881.md","text":"https://secwatch.observer/filing/0000950170-25-097881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/acet-20250722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:31:39.616366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73a5186b9b506845680ec78ed1e7b516389f37ee","claim":"Adicet Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 30% of the Company’s current employee base).","evidence_excerpt":"On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under Item 8.01 of this Current Report on Form 8-K. This workforce reduction will be substantially completed by the end of the third quarter of 2025. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $2.3 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the third quarter of 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.3 million"},{"label":"Headcount","value":"approximately 30% of the Company’s current employee base"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}